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	 A	 simple,	 sensitive	 and	 precise	 high	 performance	 liquid	 chromatographic	 method	 for	 the
analysis	 of	 atenolol	 and	 indapamide	 with	 UV	 detection	 at	 231	 nm,	 has	 been	 developed,
validated	 and	 used	 for	 the	 determination	 of	 these	 compounds	 in	 pharmaceutical	 dosage
forms,	in	human	blood	and	in	human	milk.	The	compounds	were	well	separated	on	a	Hypersil
BDS	C18	reversed‐phase	column	with	mobile	phase	consisting	of,	pH	=	3.5,	0.01	M	potassium
dihydrogen	orthophosphate	buffer‐acetonitrile	(60:40;	v:v)	at	a	flow	rate	of	1.0	mL/min.	The
method	showed	good	linearity	in	the	range	of	5‐30	µg/mL	for	atenolol	and	0.25‐1.50	µg/mL
for	indapamide.	Both	the	drugs	were	eluted	within	5	minutes	and	give	sharp	peak	with	high
theoretical	plate	count	and	low	tailing	factor.	The	reaction	time	for	atenolol	and	indapamide
was	 found	 to	 be	 2.29	 and	 3.83	 min,	 respectively.	 The	 validation	 was	 carried	 according	 to
International	 Conference	 on	 Harmonisation	 (ICH)	 guidelines.	 In	 linearity	 curve	 correlation
coefficients	 for	 atenolol	 and	 indapamide	were	 found	 to	 be	0.9995	 and	 0.9991,	 respectively.
The	percent	recovery	was	99.81‐100.02	for	atenolol	and	indapamide	indicating	accuracy	and
reliability	of	method.	So	the	method	can	be	used	for	estimation	of	these	drugs	in	tablet	dosage
form,	human	blood	and	milk.	
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1.	Introduction	
	
Development	 of	 the	 rapid	 and	 reproducible	 analytical	
methods	 for	 estimation	 of	 multicomponent	 drugs	 is	 very	
important	 part	 of	 quality	 control	 and	 for	 social	 awareness	
which	 is	 established	 in	 present	 work.	 Nowaday’s	 new	
multicomponent	formulations	in	market	increasing	with	alarm	
rate	which	have	better	synergetic	effect	it	is	very	essential	that	
two	 or	 more	 number	 of	 drugs	 should	 be	 estimated	
simultaneously.	Atenolol	in	combination	with	indapamide	used	
as	 antihypertention	 and	 β	 blocker	 in	 cardiac	 and	 diuretic	
conditions	as	sustained	release	tablets.	
Atenolol	(Figure	1)	[(R.S)‐4‐(2‐hydroxy‐3‐isopropyl‐amino‐
propoxy)	phenyl	actetamide],	is	a	cardio	selective	β‐blocker.	It	
may	 be	 used	 alone	 or	 concomitantly	 with	 other	 antihyper‐
tensive	 agents	 including	 thiazide‐type	 diuretics,	 hydralazine,	
prazonin	and	α‐methyl	dopa	[1].	It	is	reported	to	lack	intrinsic	
sympathomimetic	 activity	 and	 membrane‐stabilizing	
properties.	 Various	 adverse	 effects	 (Skin	 eruptions,	 Skin	
necrosis	 and	 connective	 tissue	 disease)	 are	 reported	 for	
atenolol.	 It	 is	 also	 contraindicated	 in	 pregnant	 women	 and	
lactating	mothers	[2].		
Several	 analytical	 methods	 have	 been	 reported	 for	 the	
determination	of	atenolol	 in	Pharmaceutical	 formulations.	The	
United	 States	 Pharmacopeia	 (2003)	 describes	 a	 method	 that	
uses	high	performance	liquid	chromatography	(HPLC)	with	UV	
detection	 for	 assay	 of	 atenolol	 tablets	 [3].	 The	 method	
recommended	 by	 British	 Pharmacopoeia	 (2001)	 involves	 UV	
spectrophotometry	[4].	In	Brazilian	Pharmacopoeia,	however	a	
method	 for	 assay	 of	 atenolol	 was	 not	 found.	 Other	 methods	
reported	 in	 the	 literature	 for	 the	determination	of	 atenolol	 in	
pharmaceutical	 formulations	 include	 visible	 spectrophoto‐
metry	 [5‐10],	 UV	derivative	 spectrophotometry	 [11,12],	HPLC	
[13],	 high	 performance	 thin	 layer	 chromatography	 [14,15],	
potentiometry	 [16‐18],	 capillary	 electrophoresis	 [19‐21]and	
voltammetry	[22,23].	
	
 
Figure	1.	Chemical	structures	of	atenolol	and	indapamide.	
	
	
Indapamide	 is	 a	 diuretic	with	 actions	 and	 uses	 similar	 to	
those	 of	 thiazide	 diuretics,	 even	 though	 it	 does	 not	 contain	 a	
thiazide	 ring	 system.	 It	 is	 used	 for	 hypertension	 and	 also	 for	
oedama,	 including	 that	 associated	 with	 heart	 failure	 [24].	
Indapamide	is	chemically	3‐(amino	sulfamoyl)‐4‐chloro‐N‐(2,3‐
dihydro‐2‐methyl‐1H‐indol‐1‐yl)	benzamide	[25].		
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The	 structure	 of	 indapamide	 is	 shown	 in	 Figure	 1.	 It	
produces	 anti‐hypertensive	 effect	 by	 diuresis	 which	 causes	
decrease	 in	 plasma	 extracellular	 fluid	 volume,	 cardiac	 output	
and	 sodium	 concentration	 intracellularly	 in	 vascular	 smooth	
muscle	 wall	 and	 also	 dampens	 responsiveness	 to	 constrictor	
stimuli	 like	 those	 of	 angiontensin	 II	 or	 nor	 adrenaline.	
Numerous	methods	 have	 been	 reported	 for	 determination	 of	
indapamide	 including	 spectrophotometric	 [26,27]	 and	 liquid	
chromatographic	 [28,29]	 methods.	 Indapamide	 active	
pharmaceutical	 ingredient	 (API)	 of	 official	 in	 British	
Pharmacopoeia	 [30]	 and	 United	 States	 Pharmacopoeia	 [31],	
while	 indapamide	tablets	are	official	 in	British	Pharmacopoeia	
[32]	and	United	States	Pharmacopoeia	[33].	
Simultaneous	determination	of	atenolol	and	indapamide	is	
not	official	in	any	Pharmacopoeia.	Combination	of	atenolol	and	
indapamide	result	in	synergistic	effect	and	thus	superior	blood	
pressure	 lowering.	Many	methods	have	been	described	 in	 the	
literature	 for	 the	 determination	 of	 atenolol	 and	 indapamide	
individually	and	in	combination	with	other	drugs.	
The	validation	of	method	carried	out	as	per	ICH	guidelines.	
This	proposed	method	is	suitable	for	the	quality	control	of	the	
raw	 materials,	 formulations,	 dissolution	 studies	 and	 can	
employed	for	bioequivalence	studies	[34,35].	
To	the	best	of	our	knowledge,	no	RP‐HPLC	(Reverse	phase	
high	 performance	 liquid	 chromatography)	 method	 has	 been	
described	for	simultaneous	estimation	of	both	drugs	in	dosage	
form,	human	blood	and	milk.	Therefore,	 it	was	thought‐worth	
while	 to	 develop	 simple,	 precise,	 accurate	 RP‐HPLC	 methods	
for	simultaneous	determination	of	atenolol	and	indapamide	in	
tablet	and	biological	fluids.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
HPLC	was	performed	with	a	Shimadzu	(Japan)	SPD‐10	A	VP	
system	comprising	an	LC‐10AT	VP	pump,	an	autosampler,	and	
an	 SPD‐10	 A	 VP	 detector.	 Data	 processing	 was	 by	 Shimadzu	
Class‐VP	software	on	a	Hewlett‐Packard	computer.	Compounds	
were	separated	on	a	250	mm	x	4.6	mm,	5	µm	particle,	Hypersil	
BDS	C18	column.		
	
2.2.	Materials	
	
Pharmaceutical	 grade	 atenolol	 and	 indapamide	 were	
pursued	 as	 gift	 sample	 by	 Torrent	 Research	 Center	
(Gandhinagar,	 India)	 Acetonitrile	 and	 ethanol	 of	 HPLC	 grade	
were	 purchased	 from	 Qualigens	 fine	 chemicals	 (Mumbai,	
India).	Water	 HPLC	 grade	was	 obtained	 from	 a	Milli‐Q	water	
purification	system.	Whatman	filter	paper	(No.	1)	was	obtained	
from	 Merck	 and	 Potassium	 dihydrogen	 orthophosphate	 of	
analytical	 reagent	grade	was	obtained	from	S.D	fine	chemicals	
(Mumbai,	India).	
	
2.3.	Chromatographic	conditions	
	
The	optimum	composition	of	mobile	phase	was	determined	
to	 be	 0.01	 M	 potassium	 dihydrogen	 ortho	 phosphates:	
acetonitrile	 (60:40,	 v:v).	 The	 pH	 of	 this	 mobile	 phase	 was	
adjusted	 to	 3.5	 with	 ortho	 phosphoric	 acid	 (85%)	 prior	 to	
delivering	 into	the	system.	 It	 is	 filtered	through	0.45	µm	filter	
and	 degassed	 using	 a	 sonicator.	 The	 analysis	was	 carried	 out	
under	 isocratic	 conditions	 using	 a	 flow	 rate	 1.0	 mL/min	 at	
room	temperature.	Chromatograms	were	recorded	at	231	nm.	
	
2.4.	Preparation	of	standard	solution	
	
Stock	solutions	of	1000	µg/mL	were	prepared	by	dissolving	
25	 mg	 of	 atenolol	 and	 1.25	 mg	 of	 indapamide	 in	 50	 mL	
volumetric	 flasks	 dilute	 to	 volume	 with	 mobile	 phase.	 From	
these	 stock	 solutions,	 working	 standard	 solutions	 having	
concentration	100	µg/mL	each	were	prepared	 by	 appropriate	
dilution.		
	
2.5.	Sample	preparation	
	
2.5.1.	Analysis	of	pharmaceutical	dosage	forms	
	
10	mg	atenolol	and	10	mg	of	indapamide	were	dissolved	in	
ethanol	 in	 100	mL	 volumetric	 flask	 and	made	 up	 the	 volume	
with	the	same	solvent	(stock	solution	of	100	µg/mL).	Aliquots	
were	appropriately	diluted.	Twenty	tablets	were	weighed;	their	
average	 weights	 determined	 and	 were	 finally	 powdered.	 The	
correct	amount	of	powder	was	dissolved	in	ethanol	by	stirring	
for	 30	 min,	 the	 excipients	 were	 separated	 by	 filtration.	
Appropriate	aliquots	were	subjected	to	above	methods	and	the	
amount	of	atenolol	and	indapamide.	
	
2.5.2.	Serum	
	
Blood	 was	 obtained	 from	 healthy	 volunteers	 and	 serum	
was	separated	by	centrifugation	at	5,000	g	for	10	min,	standard	
drug	solution	containing	8‐32	and	2‐10	µg/mL	of	atenolol	and	
indapamide	 were	 added	 to	 1	 mL	 serum	 to	 give	 five	
concentrations,	 and	 the	contents	of	 the	 tubes	were	vigorously	
shaken.	Mobile	phase	was	added	to	deproteinate	the	serum,	at	
ratio	 of	 one	 part	 serum	 to	 three	 parts	mobile	 phase,	 and	 the	
mixture	 was	 vigorously	 mixed	 by	 means	 of	 shaker.	 The	
precipitated	proteins	were	separated	by	centrifugation	at	5,000	
g	 for	 10	 min.	 Clear	 supernatant	 was	 diluted	 with	 water	 and	
injected	 directly	 for	 HPLC	 analysis	 under	 the	 conditions	
described	above.	
	
2.5.3.	Milk	
	
Drug‐free	 human	 milk	 was	 obtained	 from	 a	 healthy	
volunteer	 and	 spiked	 with	 atenolol	 and	 indapamide	 in	 the	
concentration	range	2‐64	and	1‐32	µg/mL.	Deproteination	and	
chromatographic	 analysis	 were	 described	 for	 analysis	 of	
human	serum.	
	
3.	Results	and	discussion	
	
3.1.	Optimization	of	chromatographic	conditions	
	
Because	 mobile	 phase	 pH,	 concentration	 of	 the	 organic	
modifier,	and	instrumental	conditions	have	a	substantial	effect	
on	 the	 selectivity	 and	 sensitivity	 of	 HPLC,	 the	 effects	 on	 the	
chromatographic	 separation	of	 atenolol	 and	 indapamide	were	
investigated.	The	effect	of	mobile	phase	in	the	pH	range	2.5‐4.0	
on	 the	 separation	 behaviour	 of	 was	 investigated	 first.	 The	
retention	 time	 and	 peak	 area	 of	 atenolol	 and	 indapamide	
increased	 with	 increasing	 mobile	 phase	 pH.	 Atenolol	 and	
indapamide	were	not	stable	and	strange	peaks	were	observed	
on	use	of	mobile	phase	of	pH	=	2.	These	were	plateau	between	
pH	=	3	and	4	and	the	central	point	of	the	plateau,	pH	=	3.5	was	
chosen	as	the	optimum	mobile	phase	pH.	
The	 effects	 of	 mobile	 phase	 buffer‐acetonitrile	
concentration	 on	 peak	 shape	 and	 retention	 time	 were	
examined	for	mobile	phase	concentrations	60:40	(v:v)	at	pH	=	
3.5.	As	expected	increasing	the	concentration	of	organic	solvent	
(32‐40)	 reduced	 analysis	 time.	 Peak	 shape	 was	 almost	
unchanged	for	all	mobile	phase	concentrations.	On	the	basis	of	
efficiency,	 retention	 time	 and	 peak	 symmetry,	 buffer	 ‐	
acetonitrile	(60:40;	v:v)	was	regarded	as	suitable.	
Another	 important	 condition	 affecting	 the	 retention	
behavior	of	atenolol	and	indapamide	is	mobile	phase	flow	rate.	
When	different	flowrates	from	0.6	to	1.2	mL/min	were	tested,	
parabolic	decreases	in	atenolol	and	indapamide	retention	time	
and	 peak	 areas	 were	 observed	 with	 increasing	 flowrate.	 The	
flow	rate	corresponding	to	the	smooth	part	of	the	parabola,	1.0	
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mL/min	was	chosen	as	optimum	on	the	basis	of	retention	time,	
column	pressure	and	peak	symmetry.	
Results	 from	 system	 suitability	 testing	 are	 presented	 in	
Table	 1.	 Good	 agreement	 values	 were	 observed.	 As	 a	
consequence	 the	 optimum	 conditions	 were	 determined	 as	
mobile	phase	containing	buffer‐acetonitrile	(60:40;	v:v)	at	pH	=	
3.5	and	flow	rate	1.0	mL/min,	20	µL	loop	volume,	and	detection	
wavelength	 at	 231	 nm.	 The	 chromatogram	 obtained	 from	
atenolol	and	indapamide	under	these	conditions	was	shown	in	
Figure	2.	
	
Table	1.	Validation	parameters	of	atenolol	and	indapamide	by	HPLC.	
Parameters	 Atenolol	 Indapamide
Linearity	&	range	μg/mL	 5‐30	 0.25‐1.50	
Correlation	coefficient	 0.9995	 0.9991	
Slope	 13.738	 157.640	
Intercept	 10.670	 2.295
Standard	deviation	 0.630	 0.280
Resolution	Factor	 5.859	 8.859
Tailing	Factor	 1.292	 1.337
Theoretical	plates	 3550	 7474
Limit	of	Detection	(µg/mL)	 0.520	 0.011
Limit	of	Quantification	(µg/mL)	 1.636	 0.034
Human	serum	LOD	 0.325	 0.070
LOQ	 0.55	 0.58	
Human	milk	LOD	 0.057	 0.034
LOQ	 1.720	 0.175
	
	
	
Figure	2.	Chromatogram	obtained	from	atenolol	and	indapamide	raw	
material.	
	
3.2.	Method	validation	
	
3.2.1.	Precision	
	
Under	the	optimized	conditions	the	precision	of	the	method	
was	 determined	 by	 measurement	 of	 repeatability	 (intra‐day)	
and	 intermediate	 precision	 (inter‐day)	 both	 expressed	 as	
RSD%	 (RSD:	 Relative	 standard	 deviation)	 of	 a	 series	 of	
measurements.	 Statistical	 evaluation	 of	 the	 results	 from	
determination	 of	 intra‐day	 precision	 showed	 RSD	 was	 0.174	
and	 0.172	 statistical	 evaluation	 of	 the	 result	 from	
determination	 of	 inter‐day	 variability,	 calculated	 from	 assays	
on	3	days,	showed	RSD	was	0.041	and	0.144,	respectively.	RSD	
values	below	2%	are	 indicative	of	sufficient	method	precision,	
so	both	values	are	acceptable	analytically.	
	
3.2.2.	Linearity	
	
Calibration	 plots	 (Figure	 3)	 for	 atenolol	 and	 indapamide	
standard	in	the	mobile	phase	were	constructed	by	plotting	the	
concentration	of	atenolol	and	 indapamide	against	 the	atenolol	
and	 indapamide	 peak	 area.	 Linearity	 was	 good	 in	 the	
concentration	range	to	5‐30	and	0.25‐1.50	µg/mL.	Results	from	
linear	 regression	 analysis	 of	 the	 plots	 are	 listed	 in	 Table	 1.	
Resolution	was	always	good	in	the	linear	range	studied.	
	
3.2.3.	Detection	limit	
	
The	 limits	 of	 detection	 (LOD)	 and	 quantification	 (LOQ)	
were	 calculated	 from	 integrated	 peak	 areas	 from	 the	 HPLC	
chromatogram.	The	values,	estimated	by	dividing	the	standard	
deviation	 of	 the	 regression	 equation	 by	 the	 slope	 of	 the	
equation	 and	 multiplying	 by	 3.3	 and	 10.0,	 respectively.	 The	
minimum	 limits	 at	 which	 the	 analyte	 can	 be	 readily	 detected	
(LOD)	and	quantified	(LOQ)	for	atenolol	and	indapamide	were	
0.520,	 0.011	 µg/mL	 and	 1.636,	 0.034	 µg/mL,	 respectively,	 in	
bulk	material.	
	
	
	
	
	
Figure	3. Calibration	plots	atenolol	and	indapamide
	
3.2.4.	Accuracy	
	
Accuracy	was	calculated	by	use	of	the	Equation	1.	
	
Relative	error	(%)	=	(Conc.	found	–	spiked	conc.	/	Spiked	conc.)	x	100	 			(1)	
	
and	precision	was	evaluated	by	determination	of	the	coefficient	
of	variation	CV%,	RSD%	 [(SD/mean)x100]	at	 low,	central	and	
high	concentrations	in	the	linear	range.	The	RSD%	values	were	
also	 much	 lower	 than	 the	 acceptance	 criteria,	 showing	 the	
precision	of	the	proposed	method	is	good,	as	is	apparent	from	
Table	 2.	 The	 accuracy	 values	 for	 between	 and	 within	 day	
studies	 at	 low,	 medium	 and	 concentrations	 of	 atenolol	 and	
indapamide	in	serum	and	milk	were	with	in	acceptable	limits.	
	
Table	 2.	 Results	 from	 determination	 of	 method	 accuracy	 for	 atenolol	 and	
indapamide.	
Amount	
added	µg/mL	
Amount	found	
µg/mL,	mean,	n=6	
Recovery	
%	
Accuracy	
%	
RSD	
%	
Atenolol	
0.5 0.499 99.84	 ‐0.16	 0.329
1.0 1.002 100.02	 0.02	 0.258
1.5 1.499 99.986	 ‐0.013 0.109
2.0 1.997 99.89	 ‐0.11	 0.292
Indapamide	
0.5	 0.498	 99.72	 ‐0.28	 0.390	
1.0 0.999 99.94	 ‐0.06	 0.328
1.5 1.499 99.93	 ‐0.06	 0.170
2.0 1.997 99.85	 ‐0.15	 0.278
	
3.2.5.	Specificity	
	
Specificity	 was	 checked	 by	 using	 the	 same	 column	 for	
analysis	of	the	inactive	ingredients	of	the	tablet,	to	ensure	these	
ingredients	did	not	interfere	with	the	peaks,	so	specificity	was	
regarded	 as	 sufficient	 for	 application	 of	 the	method	 to	 tablet	
analysis,	 human	 blood	 and	 milk.	 Representative	 chroma‐
tograms	was	 generated	 to	 show	other	 components	 that	 could	
be	present	 in	 the	 sample	matrix	 are	 resolved	 from	 the	parent	
analytes.	 No	 change	 was	 observed	 in	 the	 chromatogram	 of	
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atenolol	and	indapamide	in	the	presence	of	common	excipients.	
The	specificity	was	also	determined	by	injecting	human	serum	
and	milk	samples.	Therefore,	the	proposed	method	is	selective	
and	specific	for	the	drugs	
	
3.2.6.	Recovery	
	
Recovery	was	almost	100%	for	the	drug	substance	from	the	
drug	 product	 and	 accuracy	 was	 much	 better	 than	 the	
acceptance	 criteria.	 The	 same	 concentration	 was	 used	 to	
evaluate	precision	as	repeatability.	The	RSD%	values	were	also	
much	lower	than	the	acceptance	criteria,	showing	the	precision	
of	 the	proposed	method	 is	 good,	 as	 is	 apparent	 from	Table	3.	
Blank	 serum	 and	milk	 samples	 from	healthy	 volunteers	were	
collected	 tested	 for	 the	 matrix	 interferences	 with	 determine	
drugs.	An	example	of	blank	serum	and	milk	spiked	with	0.5	to	
6.0	µg/mL	of	drugs.	As	can	be	seen,	the	drugs	are	well	resolved	
with	 no	 apparent	 interferences	 from	 serum	 and	 milk	
component.	 The	 recoveries	 of	 atenolol	 were	 100.02±0.258,	
100.01±0.022,	 100.0±0.027,	 respectively,	 and	 those	 of	
indapamide	 were	 99.94±0.328,	 99.94±0.117,	 99.98±0.051.	
These	results	suggested	that	there	were	no	relevant	differences	
in	 serum	 and	 milk	 treatment	 recovery	 at	 different	
concentration	levels	for	atenolol	and	indapamide.	
	
3.3.	Application	of	the	method	to	human	serum	samples	
	
HPLC	 analysis	 of	 drugs	 in	 biological	 samples,	 for	 example	
human	serum,	usually	requires	time‐consuming	and	expensive	
sample‐preparation	 procedures.	 The	 serum	 deproteination	
technique	 used	 in	 this	 method	 was	 quite	 simple.	 The	 serum	
proteins	 are	 precipitated	 by	 addition	 of	 buffer:acetonitrile	
(60:40)	and,	after	centrifugation	at	5,000	g,	 the	supernatant	is	
injected	 directly	 for	 analysis.	 Chromatograms	 obtained	 from	
serum	 spiked	 with	 8‐32	 and	 2‐10	 µg/mL	 atenolol	 and	
indapamide	 are	 presented	 in	 Figure	 4.	 Peak	 shape	 and	 other	
characteristics	 are	 not	 different	 from	 those	 for	 standards.	
When	 the	 ratio	 of	 peak	 areas	 of	 atenolol	 and	 indapamide	 in	
serum	were	evaluated	statistically	RSD%	was	0.15	indicative	of	
good	 intra‐day	 precision.	 Inter‐day	 variability	 was	 calculated	
from	assays	on	three	days	and	RSD%	was	0.098.	Intra	and	Inter	
day	 precision	 can	 be	 regarded	 as	 acceptable	 for	 biological	
samples	 [36].	The	 results	obtained	 from	 three	determinations	
of	each	concentration	are	given	in	Table	3.		
	
	
	
Figure	4.	Chromatogram	obtained	from	analysis	of	serum	spiked	with	
atenolol	and	indapamide	
	
Table	3.	Results	 from	determination	 of	method	accuracy	 for	 serum	 spiked	
with	atenolol	and	indapamide.	
Amount	
added	µg/mL	
Amount	found		
µg/mL,	mean,	n=6	
Recovery	
%	
Accuracy	
%	
RSD	
%	
Atenolol	
2.0	 1.998	 99.90	 ‐0.10	 0.262	
4.0	 3.9984	 99.96	 ‐0.04 0.128
6.0	 6.0004	 100.0	 0.006 0.022
Indapamide	
2.0	 1.998	 99.90	 ‐0.10	 0.262	
3.0	 2.997	 99.91	 ‐0.08	 0.171	
4.0	 3.997	 99.94	 ‐0.05	 0.117	
	
 
3.4.	Application	of	the	method	to	human	milk	
	
The	 sample‐preparation	procedure	 for	milk	was	 the	 same	
as	for	serum.	It	is	apparent	from	Figure	5	that	peak	shape	and	
other	 characteristics	 after	 extraction	 of	 spiked	 human	 milk	
were	 not	 different	 from	 those	 for	 standards	 (Table	 4).	 The	
atenolol	 and	 indapamide	were	 evaluated	 statistically	 and	 the	
results	showed	 that	RSD	was	0.27	%	 indicative	of	 good	 intra‐
day	precision.	 Inter	day	variability	was	calculated	from	assays	
on	 three	 days	 and	 RSD	 was	 0.381	 not	 indicative	 of	 excellent	
precision	 for	human	milk.	LOD	and	LOQ	calculated	 for	human	
milk	 were	 0.057,	 0.034	 and	 1.720,	 0.175	 µg/mL	 for	 atenolol	
and	indapamide,	respectively.	
	
Figure	5.	Chromatogram	obtained	from	analysis	of	human	milk	spiked	with	
atenolol	and	indapamide.	
	
Table	 4.	 Results	 from	 determination	 of	 method	 accuracy	 for	 human	 milk	
spiked	with	atenolol	and	indapamide.	
Amount	
added	
µg/mL	
Amount	found	µg/mL,
mean,	n=6	
Recovery	
%	
Accuracy	
%	
RSD	%
Atenolol
3.0 2.999 99.96	 ‐0.033	 0.117
6.0 6.000 100.003	 0.003	 0.027
9.0	 8.998	 99.98	 ‐0.017	 0.056	
Indapamide	
2.0 1.998 99.93	 ‐0.070	 0.144
4.0 3.999 99.98	 ‐0.015	 0.051
6.0 5.998 99.97	 ‐0.026	 0.082
	
Human	milk	is	a	unique,	complex,	nutritionally	natural	food	
containing	 proteins,	 lipids,	 carbohydrates,	 vitamins	 and	
minerals	 [37].	 Although	 this	 composition	 can	 sometimes	 be	
troublesome	 for	 sample	 preparation,	 the	 validation	 data,	 for	
example	 precision,	 obtained	 by	 use	 of	 the	 experimental	
conditions	 described	 above	 show	 no	 problems	 were	
encountered	 and	 validation	 data	 were	 satisfactory.	 Results	
obtained	 for	 the	method	 recovery	 and	 precision	 are	 listed	 in	
Table	 5	 for	 the	 free	 drugs	 atenolol	 and	 indapamide	 in	 spiked	
human	 milk.	 Recovery	 was	 approximately	 72%	 for	 direct	
injection	 of	 the	 clear	 supernatant	 and	 there	 were	 no	
interferences	 from	the	milk	matrix.	Human	milk	contain	quite	
different	 components	 from	 plasma,	 for	 example	 lipids	 and	
protein	 in	 high	 and	 variable	 quantities,	 it	 can,	 therefore,	 be	
more	difficult	 to	handle	than	plasma.	There	have	been	reports	
of	factors	affecting	drug	concentrations	in	milk	[37].	First,	they	
can	be	affected	by	protein	binding.	Second	milk	in	slightly	more	
acidic	 than	 maternal	 blood	 so	 weak	 bases	 will	 ionize	 to	 a	
greater	extent	 in	milk	 than	 in	plasma.	Third,	 fat	 soluble	drugs	
will	dissolve	preferentially	 in	 the	 lipid	component	of	milk	and	
may,	therefore,	not	be	available	for	diffusion	back	 into	plasma	
[36‐39].	 Low	 recoveries	 of	 atenolol	 and	 indapamide	 from	
human	 milk	 could	 be	 a	 result	 of	 these	 factors,	 especially	
possible	solubility	in	fat	and	protein	binding.	
The	 results	 show	 that	 determination	 of	 atenolol	 and	
indapamide	 in	 human	milk	 can	 be	 achieved	 successfully	 after	
use	 of	 a	 simple,	 selective	 and	 rapid	 sample‐preparation	
technique.	
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Table	5.	Precision	of	atenolol	and	indapamide	in	dosage	forms,	serum	and	milk	samples.	
Atenolol	 Indapamide	
Conc.	spiked	
Inter‐day		 Intra‐day
Conc.	spiked	
Inter‐day	 Intra‐day	
Recovery	±	RSD%	 Recovery ±	RSD% Recovery ±	RSD% Recovery	±	RSD%
Formulations	
1.0	 99.98±0.381	 99.92±0.277	 0.4	 99.95±0.447	 100.10±0.335	
2.0	 99.94±0.159	 99.81±0.222 0.8 100.15±0.240 100.12±0.197
4.0	 99.98±0.041	 99.90±0.174	 1.2	 99.91±0.144	 99.95±0.172	
Serum	
1.0	 99.86±0.313	 99.60±0.158 0.4 99.95±0.410 100.00±0.395
1.5	 99.92±0.098	 99.92±0.098	 0.8	 100.00±0.197	 99.98±0.186	
2.0	 99.98±0.115	 99.76±0.233	 1.2	 99.91±0.108	 99.98±0.180	
Milk	
0.5	 99.76±0.297	 100.02±0.340 0.6 99.90±0.401 100.06±0.383
1.0	 99.80±0.381	 99.92±0.277 0.8 100.00±0.197 100.07±0.259
1.5	 99.96±0.138	 99.69±0.223	 1.0	 99.98±0.303	 100.02±0.268	
	
	
4.	Conclusion	
	
A	simple	and	rapid	RP‐HPLC	method	for	 the	simultaneous	
determination	of	atenolol	and	 indapamide	 in	pharmaceuticals,	
human	 serum	 and	 human	 milk	 has	 been	 developed	 and	
validated	in	this	study.	The	retention	times	observed	(2.29	and	
3.83	 min)	 enable	 rapid	 determination	 of	 the	 drugs,	 which	 is	
important	 for	 routine	 analysis.	 The	 linearity	 range,	 limits	 of	
detection	 and	 quantifications,	 precision	 and	 accuracy	 were	
determined	 to	 asses	 the	 suitability	 of	 the	 method	 and	
satisfactory	results	were	obtained.	This	HPLC	method	with	UV	
detection	 has	 several	 advantages	 over	 other	 methods.	 In	 the	
proposed	method	the	analysis	time	is	quite	short	and	a	simple	
mobile	 phase	 is	 used,	 for	 this	 reason	 consumption	 of	 organic	
solvent	 is	very	 low.	The	method	 is	 rapid,	specific,	 reliable	and	
cost‐effective	 and	 can	 be	 recommended	 for	 routine	 analysis	
and	for	quality	control.	
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